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ABSTRACT
Poly (ADP-ribose) is synthesized at DNA single-
strand breaks and can promote the recruitment of the
scaffold protein, XRCC1. However, the mechanism
and importance of this process has been challenged.
To address this issue, we have characterized the
mechanism of poly (ADP-ribose) binding by XRCC1
and examined its importance for XRCC1 function. We
show that the phosphate-binding pocket in the cen-
tral BRCT1 domain of XRCC1 is required for selective
binding to poly (ADP-ribose) at low levels of ADP-
ribosylation, and promotes interaction with cellular
PARP1. We also show that the phosphate-binding
pocket is required for EGFP-XRCC1 accumulation
at DNA damage induced by UVA laser, H2O2, and at
sites of sub-nuclear PCNA foci, suggesting that poly
(ADP-ribose) promotes XRCC1 recruitment both at
single-strand breaks globally across the genome and
at sites of DNA replication stress. Finally, we show
that the phosphate-binding pocket is required follow-
ing DNA damage for XRCC1-dependent acceleration
of DNA single-strand break repair, DNA base excision
repair, and cell survival. These data support the hy-
pothesis that poly (ADP-ribose) synthesis promotes
XRCC1 recruitment at DNA damage sites and is im-
portant for XRCC1 function.
Single-strand breaks (SSBs) are the commonest lesions
arising in cells, resulting both directly from disintegration
of deoxyribose and indirectly during the excision repair of
DNA base damage [reviewed in (1)]. SSBs usually lack con-
ventional 3′-hydroxyl and 5′-phosphate termini, often pos-
sessing modifications such as 3′-phosphate or 5′-hydroxyl
termini, or fragments of deoxyribose or topoisomerase. If
not repaired rapidly, such termini can block progression
of RNA or DNA polymerases, disrupting transcription or
replication, respectively. The threat posed by SSBs is indi-
cated by the existence of human genetic diseases associated
with neurological dysfunction in which single-strand break
repair (SSBR) is attenuated (1).
To date, all known SSBR-defective diseases are associ-
ated with defects in end processing, the step of repair dur-
ing which conventional 3′-hydroxyl and 5′-phosphate ter-
mini are restored. One critical component of end process-
ing is XRCC1, a molecular scaffold protein that interacts
with and recruits, stabilizes, and/or stimulates end process-
ing enzymes and accelerates SSBR ∼5-fold (2,3). The im-
portance of XRCC1 is illustrated by the hypersensitivity of
XRCC1-mutant cells to a broad range of genotoxins and
to their elevated frequency of chromosome aberrations, ge-
netic deletions and sister chromatid exchanges (4–6). More-
over, mice with conditional deletion of Xrcc1 in brain re-
capitulate many of the pathologies associated with loss of
SSBR in humans, including cerebellar defects, ataxia and
seizures (7).
A number of observations suggest that XRCC1 re-
cruitment at chromosomal SSBs is promoted by poly
(ADP-ribose) (PAR) synthesis. First, XRCC1 interacts
directly with both PAR and with the poly (ADP-
ribose) polymerases PARP1 and PARP2 (8–10). Second,
small molecule-mediated inhibition of PAR synthesis, or
depletion/deletion of PARP1, greatly reduces the accumu-
lation of XRCC1 at sites of H2O2 or UV laser-induced
DNA damage (11–15). Third, mutations that disrupt fold-
ing of the PAR-binding BRCT1 domain in XRCC1 re-
duce or ablate XRCC1 accumulation at DNA damage
(9,11,15,16). Finally, depletion of PARG, the enzyme re-
sponsible for PAR degradation following SSBR, increases
both steady state cellular levels of PAR and the accumula-
tion and/or persistence of XRCC1 in sub-nuclear foci be-
fore and after DNA damage (17).
Despite these observations, however, several recent re-
ports have challenged the importance of PAR binding for
XRCC1 function, instead ascribing XRCC1 recruitment to
DNA binding protein partners such as DNA polymerase
 (Pol), polynucleotide kinase/phosphatase (PNKP), and
DNA ligase III (Lig3) (18–22). One reason this uncer-
tainty remains is a lack of clarity concerning themechanism
of PAR binding by XRCC1. PAR binding was first ascribed
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to a degenerate motif present at the C-terminus of the cen-
tral BRCT1 domain in XRCC1, comprised of an alternat-
ing series of basic/hydrophobic residues and present in nu-
merous other PAR binding proteins (9). However, a recent
study instead assigned PAR binding to the phosphate bind-
ing pocket present in the BRCT1 domain (16). Not know-
ing the site of PAR interaction has prevented the generation
of point mutations that specifically reduce or ablate PAR
binding, and consequently an analysis for their impact on
XRCC1 function. Here, we have confirmed the site of PAR
binding in XRCC1, enabling us to mutate this site and ad-
dress directly, for the first time, its importance for XRCC1
cellular function.
MATERIALS AND METHODS
Cell lines
The osteosarcoma cell line U2OS (obtained from the
Genome Damage and Stability Centre cell repository)
and derivatives of the Chinese hamster ovary (CHO) cell
line EM9 (4) were maintained as monolayers in modi-
fied Eagle’s medium (MEM) or Dulbecco’s modified Ea-
gle’s medium (DMEM), respectively, supplemented with
10% (vol/vol) foetal calf serum, 100 U/ml penicillin, 2 mM
glutamine and 100 g/ml streptomycin. Expression con-
structs were introduced into the XRCC1-mutant CHO cell
line EM9 by Genejuice transfection (Novagen) and sta-
ble cell lines prepared by selection in media containing 1.5
mg/ml G418 (Gibco-Invitrogen) for 10–14 days. The cell
line U2OSGFP-XRCC1 was generated by transfection of 1 ×
106 U2OS cells with 0.5 g pEGFP-XRCC1 by nucleofec-
tion (Lonza kit V) according to the manufacturer’s instruc-
tions. Twenty four hours after nucleofection, cells were se-
lected in media containing 1 mg/ml G418 for 3 weeks and
single clones selected based on their level of GFP expres-
sion. One clone, denoted U2OSGFP-XRCC1, was selected for
further use.
XRCC1, PARP1 and PCNA expression constructs
To create pCD2EXHR335A,K369A (denoted pcD2EXHRK),
encoding human XRCC1-His R335A,K369A, the
XRCC1 ORF in pCD2EXH (23) was mutated
using a QuikChange Mutagenesis Kit (Agi-
lent Technologies) using the oligonucleotides 5′-
CCAGAACCCCTTCGCCTCCGAGCTGCGAG-3′ and
5′-TGCCAACACCCCCGCGTACAGCCAGGTCC-
3′. All mutated ORFs were confirmed by se-
quencing. To create pmRFP-XRCC1161–406 and
pmRFP-XRCC1161–406 RK, encoding human mRFP-
XRCC1161–406 and mRFP-XRCC1161–406 RK, respec-
tively, cDNA encoding XRCC1 residues 161–406
was amplified by PCR using the oligonucleotides 5′-
AAGAATTCCATGCACCATCACCATCACCATCC
GTCCCAGAAGGTGACAGTG-3′ (forward) and 5′-
CCCGAATTCTGCAGTCATGGCCCTGCCATGAG
GTA-3′ (reverse) and either pCD2EXH or pCD2E-XHRK
as template, as appropriate. Note that these constructs
also possess an N-terminal histidine tag (underlined).
PCR products were verified by sequencing and cloned
into the EcoR1 site of pmRFP (24). PARP1-pmCherry
and PARP1E988K-pmCherry were kind gifts from Gyula
Timinszky (Ludwig-Maximilians University, Munich).
pCCC-TagRFP is a chromobody-Tag plasmid encoding
PCNA-VHH fused to RFP (Chromotek), which enables
detection of endogenous PCNA.
Western blotting
Proteins were fractionated on 8% or gradient SDS-PAGE
gels and transferred onto nitrocellulose membrane (GE
Healthcare). Membranes were blocked in 5% non-fat dried
milk/TBST for 30 min at room temperature or overnight
at 4◦C. After washing, blocked membranes were incubated
with rabbit anti-GFP polyclonal antibody (#2555, Cell Sig-
nalling Technology), rabbit anti-phospho (pS485/pT488)
XRCC1 polyclonal antibody (1:5000; A300-231A; Bethyl
Laboratories, Inc.), mouse anti-PAR (10H) Mab (1:1000),
mouse anti-PARP1 Mab (1:1000, MCA1522G, Bio-Rad),
mouse anti-ActinMab (1:2000, A4700, Sigma), mouse anti-
XRCC1 (33-2-5) Mab (23), or mouse anti-polyhistidine
(His-tag) Mab (Sigma). Anti-mouse and anti-rabbit HRP-
conjugated secondary antibodies (Dako Cytomation) were
employed at 1:5000, in 5% non-fat milk for 1 h at room tem-
perature. Detection was by ECL (GE Healthcare) and au-
toradiography.
Transfection and fluorescence imaging
U2OS cells or U2OSGFP-XRCC1 cells were seeded onto cov-
erslips and transfected 1 day later with appropriate con-
structs using FuGENE 6 transfection reagent according
to the manufacturer (Promega). Twenty four hours later,
the cells were mock-treated or treated with 10 mM H2O2
for 10 min, incubated at 37◦C in drug free media for 15
min, washed with phosphate buffered saline (PBS) and
then fixed for 10 min in 4% paraformaldehyde in PBS at
room temperature. After fixation the cells were washed 2×
with PBS, treated with ice-cold methanol/acetone solu-
tion for 10 min, washed 2× with PBS and mounted us-
ing VECTASHIELD Mounting Media. Images were cap-
tured on a Leica SP8 confocal microscope. For EdU la-
beling of sites of DNA replication, the Click-iT R© EdU
Alexa Fluor R© 647 Imaging Kit fromMolecular Probes was
used according tomanufacturer’s instructions. For laser mi-
croirradiation, 2 × 105 EM9 cells were seeded onto glass-
bottom dishes (Mattek) and transfected with 1 g of the
indicated pmRFP-XRCC1 construct usingGenejuice (Mili-
pore). Twenty four hours later, cells were pre-incubatedwith
10 g/ml Hoechst 33258 (for micro-irradiation with a 351
nm laser) or Hoechst 34580 (for a 405 nm laser) for 30
min prior to localised micro-irradiation with a 351 nm or
405 nm UV-laser at a dose of 0.22 J/m2 as previously de-
scribed (25). Time-lapse images were recorded at the inter-
vals shown after micro-irradiation. For experiments with
PARP inhibitor, cells were pre-incubated with either 100
nM Olaparib (Selleckchem) as indicated or with 500 nM
Ku58948 (AstraZeneca) 30 min before micro-irradiation.
Clonogenic survival assays
The indicated cells (500) were plated in duplicate in 10 cm
dishes and incubated for 4 h at 37◦C. Cells were rinsed with
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PBS and either mock treated or treated with H2O2 (diluted
in PBS at the indicated concentration immediately prior to
use) or methyl methanosulfonate (MMS) (diluted in com-
plete medium at the indicated concentration immediately
prior to use) for 15min at room temperature (H2O2) or 37◦C
(MMS). After treatment, cells were washed twice with PBS
and incubated for 10–14 days in drug-free medium at 37◦C
to allow formation of macroscopic colonies. Colonies were
fixed in ethanol (95%), stained with 1% methylene blue in
70% ethanol and colonies of >50 cells counted. Percentage
survival was calculated for each drug concentration using
the equation 100 × [average mean colony number (treated
plate)/average mean colony number (untreated plate)].
Alkaline single cell agarose gel electrophoresis (alkaline
comet assay)
Sub-confluent cell monolayers were trypsinised, diluted to
2 × 105 cells/ml in ice-cold PBS (for H2O2 treatment) or
complete media (for MMS treatment) immediately prior to
treatment, and either mock-treated or treated with 150 M
H2O2 (diluted in ice-cold PBS immediately prior to use) for
20 min on ice or with the indicated concentration of MMS
(diluted in complete medium) for 15 min at 37◦C. Cells were
then rinsed in ice-cold PBS and incubated, where appropri-
ate, in fresh drug-free media for the desired repair period at
37◦C. Cells (100 per data point) were then analysed by alka-
line comet assay as previously described (26) using Comet
Assay IV software (Perceptive Instruments).
Expression and purification of His-XRCC1161–406 and His-
XRCC1161–406 RK
For expression of recombinant XRCC1 proteins, we
employed RosettaTM2 (DE3)pLysS (Merck Millipore) Es-
cherichia coli harbouring the expression plasmids pTWO-
E-His-XRCC1161–406 or pTWO-E-His-XRCC1161–406 RK.
pTWO-E is modified from pET-17b, encoding an N-
terminal Rhinovirus 3C-cleavable, His6 affinity tag. For
XRCC1 expression, 100ml LB ampicillin/chloramphenicol
media was inoculated with a single bacterial colony and
incubated with shaking (220 rpm) at 37◦C for 8 h and
then stored at 4◦C overnight. The next day, 6× 1 l of
LB-ampicillin/chloramphenicol media supplemented
with antibiotics as above was inoculated with the starter
culture (10 ml/l) and again incubated, with shaking, at
37◦C until and OD600 of 0.8–1.0 was reached, after which
protein expression was induced by the addition of 0.2 ml
1 M IPTG/litre for a period of 3 h at 30◦C. Cells were
harvested by centrifugation and the resulting pellet stored
at −20◦C. For purification, cell pellets were thawed on ice,
resuspended in 50 mM HEPES pH 7.5, 250 mM NaCl, 10
mM imidazole and 1 mM Tris(2-carboxyethyl)phosphine
(TCEP), and lysed by sonication on ice for 10 min (10 s
on/10 s off) using a large parallel probe at 25% amplitude
(Sonics Vibra-Cell, VWR). The lysate was clarified by
centrifugation for 50 min at 40 000 × g at 4◦C and the
resulting supernatant added to a 5 ml bed volume of Talon
resin (Clontech) in a gravity flow column. After 30 min
incubation with the resin, with mixing at 4◦C, unbound
material was removed by sequential washes (3 × 10 ml)
with resuspension buffer. Bound protein was eluted by
addition of (2 × 5 ml) elution buffer (50 mM HEPES
pH7.5, 250 mM NaCl, 300 mM imidazole and 1 mM
TCEP). The eluate was loaded onto a pre-equilibrated (20
mMHEPES pH 7.5, 150 mMNaCl and 1 mMTCEP) 5 ml
FF Heparin column (GE Healthcare) and bound material
eluted with a linear salt gradient (20 mMHEPES pH 7.5, 1
M NaCl and 1 mM TCEP). Fractions containing XRCC1
were identified by SDS-PAGE, then pooled and concen-
trated, using Vivaspin 20 (10 000 MWCO) centrifugal
concentrators (Sartorius Stedim), to a final concentration
of 0.3 mg/ml, and then stored at −80◦C until required.
Thermal denaturation and circular dichroism
For thermal denaturation, samples containing 2.0 M
protein and 5× SYPRO Orange (diluted from a 5000 ×
stock supplied in DMSO; catalogue number S5692, Sigma–
Aldrich) were prepared in sample buffer [50 mM HEPES
pH 7.5, 300 mM NaCl, 0.5 mM TCEP and 5× Sypro Or-
ange (from Sigma–Aldrich R©)]. Denaturation curves were
monitored in 96-well PCR plates in a Roche LightCycler
480 II, using 465 and 580 nm filters for excitation and
emission wavelengths, respectively. Temperature midpoints
(Tm) for each folded to unfolded transition were determined
by non-linear regression fitting of a modified Boltzmann
model (27) to normalized data in Prism5 (GraphPad Soft-
ware).
Y = (anX+ bn) + (ad X+ bd ) − (anX+ bn)
1 + e Tm−Xm
where: an and ad are the slopes, bn and bd the y-intercepts,
of the native and denatured baselines, respectively. Tm is the
melting temperature and m a slope factor.
For circular dichroism, spectra were measured at 20◦C
between the wavelengths 198 and 280 nm in a JASCO J-
715 spectropolarimeter attached to a JASCO PTC-384W
temperature control system. CD spectra were measured us-
ing a 0.1 mm path length cell (Starna Scientific), with pro-
tein at a concentration of 54 M, that had been buffer-
exchanged into 10 mMHEPES pH 7.5, 300 mMNaCl, 0.5
mM TCEP. Spectra were measured using a 0.1 mm path
length cell (Starna Scientific) and represent the average of
10 consecutive scans, where the signal from buffer alone has
been subtracted.
Poly (ADP-ribose) binding assays
The wells of flat bottomed 96 well PS-microplates (Greiner)
were incubated with either 50 l recombinant histone
H1, PARP1 or BSA at 0.1 mg/ml in PBS overnight at
4◦C and the wells rinsed (4×) with 0.2 ml 0.1% Triton
X100 in PBS. The adsorbed proteins were mock ribosy-
lated in the absence of NAD+ or ribosylated in the pres-
ence of the indicated concentration of NAD+ (Sigma)
in PARP1 reaction buffer (50 mM Tris–HCl pH8, 0.8
mM MgCl2, 1% glycerol and 1.5 mM DTT) containing
40 nM single-stranded oligodeoxyribonucleotide (Eurogen-
tec: 5′-CATATGCCGGAGATCCGCCTCC-3′) and 5 nM
PARP1 (recombinant, human, full length) in a final volume
of 50 l at room temp for 30 min. After rinsing (4×) with
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50 l of 0.1% Tween 20 in PBS, 50 l of His-XRCC1161–406
or His-XRCC1161–406 RK (diluted to 25 nM in 20 mM Tris
pH7.5, 130 nM NaCl) was added to the adsorbed pro-
teins and incubated on ice for 30 min. Where indicated,
His-XRCC1 proteins were pre-incubated withmono (ADP-
ribose) or poly (ADP-ribose)(Trevigen) competitor at the
concentrations indicated for 30 min at 4◦C, before their
addition to the adsorbed proteins. The wells were then
rinsed (4×) as above and incubated with 50 l mouse anti-
polyhistidine (His-tag) Mab (Sigma, diluted 1: 3000 in 20
mM Tris pH7.5, 130 nM NaCl) followed by 50 l HRP-
conjugated rabbit anti-mouse IgG (Dako, 1: 5000 in dilu-
tion buffer) for 30 min each on ice. After a final wash with
0.1% Tween 20 in PBS, 50 l of TACS Sapphire (Trevigen)
was added to the wells, incubated in the dark for 15 min,
stopped by adding 0.2MHCl, and the absorbance was read
at 450 nm.
GFP pull down experiments
U2OSGFP-XRCC1-His cells (see above), or U2OS cells 48 h af-
ter nucleofection (Amaxa; Lonza, Slough, UK) with 4 g
each of pEGFP-XRCC1161–406 or pEGFP-XRCC1161–406 RK
and either pmCherry-PARP1 or pmCherry-PARP1E988K
were snap frozen until needed. Cells were then thawed on
ice and lysed on ice for 20 min in 0.4 ml/5 × 106 cells
in 25 mM HEPES (pH 7.8), 150 mM NaCl, 10% glyc-
erol, 0.5% Triton X-100, and including Protease Inhibitor
Cocktail and Phosphatase Inhibitor Cocktail 3 (Sigma-
Aldrich R©, Dorset, UK). Where indicated, the PARP1 in-
hibitor KU58948 (500 nM) was added to the cell culture
medium 1 h prior to cell harvest and/or was included in the
cell lysis buffer. Lysed cells were sonicated in a Bioruptor
and clarified by centrifugation at 4◦C. Unless stated other-
wise, all subsequent steps were performed on ice. Forty mi-
croliters of the clarified extract was retained on ice as ‘input’
and 360 l was mixed with 15 l (bed volume) of GFP-
Trap A beads (ChromoTek GmbH, Germany) prewashed
in 0.5 ml wash buffer (lysis buffer containing 1 mM DDT
and 25 mM imidazole). After 1 h on a carousel at 4◦C,
the GFP-Trap R© A beads were gently pelleted by centrifu-
gation at 2000 × g for 2 min. Sixty microliters of the su-
pernatant was retained as ‘unbound’ material and the pellet
was washed three times in wash buffer, with 50 l of the fi-
nal wash retained as ‘final wash’. Proteins were eluted from
the beads by re-suspension in 50 l 2× Laemmli buffer (250
mMTris (pH 8.0), 10% SDS, 500 mMDTT, 50% glycerol)),
heating for 5 min at 95◦C, and centrifugation at 2700 × g
for 2 min to recover the supernatant.
RESULTS
To further examine the importance of PAR binding for
XRCC1 functionwe first addressed the location of the PAR-
binding site. The most evolutionary conserved and func-
tionally important region of XRCC1 is the central BRCT1
domain that mediates binding to PAR (see Figure 1A) (28).
PAR-binding by the BRCT1 domain was initially ascribed
to a degenerate motif of hydrophobic/basic amino acids
that is present in many PAR binding proteins (Figure 1B,
dotted red box) (9). However, a different putative PAR-
binding motif in BRCT1 was recently reported, comprised
of the phosphate-binding pocket common to several other
BRCT domains (Figure 1B, solid red boxes and Figure
1C) (16). Within this pocket, Ser328, Arg335 and Lys369
are all predicted to contribute to phosphate binding, based
on the structure of other phosphate-binding BRCT do-
mains of this type. Consequently, for subsequent analysis in
vitro, we expressed and purified both a wild-type histidine-
tagged fragment of human XRCC1 spanning the conserved
BRCT1 domain (denoted His-XRCC1161–406) and a mutant
derivative in which both Arg335 and Lys369 were mutated
toAla (denotedHis-XRCC1161–406 RK) (Figure 1D, left).We
employed both mutations because mutation of R335 alone
failed to have any measurable impact on XRCC1 function
(data not shown).
Next, to confirm PAR binding by the BRCT1 phosphate-
binding pocket we adsorbed PARP1, histone H1, or
BSA to microwell plates, mock-ribosylated or ribosylated
these proteins with PARP1 in the absence or presence of
NAD+, respectively, and compared their binding to His-
XRCC1161–406 and His-XRCC1161–406 RK, in vitro (Figure
1D, right). Wild-type His-XRCC1161–406 bound both to ad-
sorbed PARP1 and histone H1, if these proteins were first
ribosylated in the presence of 1–50 M NAD+, and was
fully bound even at the lowest concentration of NAD+ em-
ployed (1M) (Figure 2A, blue bars). In contrast, relatively
little binding was observed to BSA, irrespective of whether
or not it was first incubated with PARP1 and NAD+, con-
sistent with this protein being a poor substrate for PARP1.
More importantly, His-XRCC1161–406 RK bound ribosylated
PARP1 and histone H1 to a much lesser extent, and not at
all at the lowest concentration (1 M) of NAD+ employed
(Figure 2A, red bars). This did not reflect a non-specific im-
pact of the mutations on folding of the BRCT1 domain,
because His-XRCC1161–406 and His-XRCC1161–406 RK ex-
hibited similar thermal stabilities and circular dichroism
spectra (Figure 2B). Importantly, His-XRCC1161–406 bound
specifically to PAR in these experiments, because it was sup-
pressed by a 8-fold molar excess of ADP-ribose competi-
tor if present as polymer (PAR), but was not suppressed
even at 500-fold molar excess if present as ADP-ribose
monomer (MAR) (Figure 2C). These data confirm that the
phosphate-binding pocket of the XRCC1 BRCT1 domain
promotes binding to PAR in vitro, particularly at low levels
of poly (ADP-ribosylation).
Next, we examined whether PAR binding by the
phosphate-binding pocket is physiologically relevant, by
comparing wild type and mutant XRCC1 for interac-
tion with cellular PARP1. As expected, full length EGFP-
XRCC1 co-precipitated endogenous PARP1 from stably
transfected U2OS cells (U2OSGFP-XRCC1 cells; see ’Materi-
als and Methods’ section) in a manner that was inhibited
by PARP inhibitor (Figure 3A). Similarly, truncated EGFP-
XRCC1161–406 spanning the BRCT1 domain co-precipitated
mCherry-PARP1 in transient co-transfection experiments,
but co-precipitated mutant mCherry-PARP1E988K lacking
polymerase activity (29,30) to a much lesser extent (Figure
3B). More importantly, EGFP-XRCC1161–406 RK was also
less able to pull-down wild type mCherry-PARP1, confirm-
ing that the phosphate-binding pocket promotes interac-
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Figure 1. Conservation of the XRCC1 BRCT1 domain and its phosphate-binding pocket. (A) Schematic depicting conservation of XRCC1 domains in
human (Hs), frog (Xl), fly (Dm), and plant (At) XRCC1. Binding sites for the indicated protein partners are shown. Asterisks denote CK2 phosphorylation
sites that mediate FHA-dependent interactions with PNKP, APTX and APLF. Black boxes denoted the nuclear localization signal. (B) Alignment of the
BRCT1 domain from human, frog, fly and plant. Solid red boxes denote the residues predicted to form the phosphate-binding pocket and the dotted red
box denotes the degenerate putative PAR-binding motif identified by Pleschke et al. (9). Conserved identical residues are in red. Asterisks denote residues
mutated in this study. (C) Model of the BRCT1 domain based on the NMR structure (PDN accession code: 2D8M), highlighting the residues predicted to
form phosphate-binding pocket. (D) Left, purified recombinant His-XRCC1161–406 and His-XRCC1161–406 RK proteins, fractionated by SDS-PAGE and
stained with coomassie brilliant blue. Right, cartoon of the in vitro PAR-binding assay. Proteins were adsorbed to microwell dishes and mock-ribosylated
(‘-NAD+’) or ribosylated (‘+NAD+’) by PARP1 in absence or presence of NAD+ as indicated. Bound proteins were then incubated with recombinant
wild type His-XRCC1161–406 or mutant His-XRCC1161–406 RK, and bound XRCC1 detected with anti-His tag antibodies colourmetrically (A450) using
HRP-conjugated secondary antibody.
tion with PARP1 (Figure 3B). Consistent with these data,
mRFP-XRCC1161–406 rapidly accumulated at sites of UVA
laser damage at a rate similar to full-length mRFP-XRCC1
and in a manner that was greatly inhibited by PARP in-
hibitor (500 nMKu58948), suggesting that the region span-
ning the BRCT1 domain is sufficient for XRCC1 accumu-
lation at sites of cellular PAR synthesis (Figure 3C and
D). Note that we confirmed previously that this concen-
tration of Ku58948 greatly reduces or ablates PAR syn-
thesis in UVA laser tracks (31). In contrast, neither full-
length mRFP-XRCC1RK nor mRFP-XRCC1161–406 RK ac-
cumulated at sites of UVA laser damage (Figure 3C and D).
Similarly, full-length EGFP-XRCC1RK failed to accumu-
late in sub-nuclear foci at sites of H2O2-induced oxidative
stress, confirming that the phosphate-binding pocket is also
required for accumulation of EGFP-XRCC1 at this more
physiologically relevant source of SSBs (Figure 4A).
XRCC1 has also been reported to colocalise with PCNA
in replication foci in human cells, consistent with its pro-
posed role during SSBR at sites of stalled or collapsed repli-
cation forks (1,32–35). However, whether XRCC1 accumu-
lation at such sites is also regulated by PAR synthesis is
not known. Indeed, the accumulation of EGFP-XRCC1 in
sub-nuclear foci with endogenous PCNA, detected by ex-
pression of anti-PCNA antibody, was greatly reduced by
PARP inhibitor in both early and late S phase cells (Fig-
ure 4B, left panels). We confirmed in these experiments that
the sites of PCNA and EGFP-XRCC1 colocalisation were
sites of DNA replication, by pulse labeling with EdU (Fig-
ure 4B, right panels). Importantly, EGFP-XRCC1 accu-
mulation at sites of PCNA accumulation was greatly re-
duced or ablated by mutation of the phosphate-binding
pocket, suggesting that PAR binding is also critical for
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Figure 2. TheXRCC1BRCT1 phosphate-binding pocket binds PAR, in vitro. (A) Binding of His-XRCC1161–406 andHis-XRCC1161–406 RK to the indicated
mock-ribosylated (-NAD+) or ribosylated (1–50 M NAD+) proteins was measured as indicated in Figure 1D. Data are the mean (±1 SD) of at least
three experiments. (B) Top, thermal stability of recombinant His-XRCC1161–406 and His-XRCC1161–406 RK. 2 M XRCC1 protein was assayed in the
presence of SYPROOrange and unfolding temperatures determined as described in materials andmethods. Data are the mean (±1SD) of four independent
measurements. Bottom, circular dichroism of His-XRCC1161–406 and His-XRCC1161–406 RK. Data are the average of 10 sequential scans, with the spectrum
from sample buffer alone subtracted. (C) Binding of His-XRCC1161–406 and His-XRCC1161–406 RK to calf thymus histone mock-ribosylated in the absence
of NAD+ (‘0’) or ribosylated in the presence of either 0.5 M NAD+ (left panel) or 1 M NAD+ (right panel). Where indicated, XRCC1 binding was
measured in the presence of 43 nM PARP1 competitor that was first autoribosylated in the presence of 0, 0.2, 0.4, 0.8 or 2 M NAD+, as indicated.
Alternatively, His-XRCC1161–406 and His-XRCC1161–406 RK binding was measured the presence of the indicated concentration of either poly (ADP-ribose)
(‘PAR’, left) or mono (ADP-ribose) (‘MAR’, right) competitor. PAR/MAR competitor concentrations are total ADP-ribose units (M) present as PAR
(2–300 subunit lengths) or MAR. Data are the mean (±1SD) of at least three experiments.
the recruitment/accumulation of EGFP-XRCC1 at sites of
DNA replication (Figure 4C).
Finally, to address the importance of the phosphate-
binding pocket for XRCC1 function, we employed deriva-
tives of XRCC1-mutant EM9 cells stably transfected with
either empty vector (EM9-V) or with expression vector en-
coding either full-length human XRCC1-His (EM9-XH)
or XRCC1-HisRK (EM9-XHRK) (Figure 5A). In contrast
to XRCC1-His, XRCC1-HisRK was unable to promote cell
survival in XRCC1-mutant EM9 cells much more than
empty vector, following H2O2 or MMS treatment (Figure
5B). This was also true in experiments inwhichwemeasured
rates of chromosomal SSBR using alkaline comet assays, in
which XRCC1-HisRK again failed to correct the slow rate
of DNA strand break repair observed in EM9 cells (Figure
5C).
Collectively, these data demonstrate that the XRCC1
phosphate-binding pocket binds PAR in vitro and in cells,
promotes XRCC1 accumulation at sites of DNA damage,
and is required for XRCC1 cellular function.
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Figure 3. The XRCC1 BRCT1 phosphate-binding pocket mediates PAR-dependent interaction with PARP1 and recruitment at sites of UVA laser induced
damage. (A) EGFP-XRCC1 was affinity purified from cell extract from U2OSGFP-XRCC1 cells using GFP-Trap beads. Aliquots of the column input,
unbound, last wash, and eluate samples were fractionated by SDS-PAGE and immunoblotted with pS485/pT488 anti-XRCC1 polyclonal antibody or anti-
PARP1 antibody. Where indicated (‘+PARPi’), PARP inhibitor (500 nM Ku-58948) was included in the cell lysis buffer and was present in the cell culture
medium for 1 h at 37◦C prior to lysis. (B) U2OS cells were transiently co-transfected with expression vector encoding either EGFP, EGFP-XRCC1161–406,
or EGFP-XRCC1161–406 RK and with expression vector encoding either mCherry-PARP1 or mCherry-PARP1E988K. EGFP-XRCC1 was recovered from
whole cell extract and aliquots of column input, unbound, last wash and eluate (bound material) fractionated by SDS-PAGE and immunoblotted with
anti-GFP or anti-PARP1 antibody. The position of mCherry-PARP1 and endogenous PARP1 are indicated by black and red arrows, respectively. (C)
XRCC1-mutant EM9 cells were transiently transfected with pmRFP-XRCC1, pmRFP-XRCC1RK, pmRFP-XRCC1161–406, or pmRFP-XRCC1161–406 RK
and treated with UVA laser. mRFP fluorescence was measured at the indicated times (seco) following microirradiation in the presence or absence of 500nM
PARP inhibitor (Ku-58948). Representative images are shown. (D) Left, quantitation of the mRFP-XRCC1 fluorescence proteins at sites of 405 nm UVA
laser-inducedDNAdamage in the above experiments. Inset, pmRFP-XRCC1 and pmRFP-XRCC1RK expression levels in the transfected cells, asmeasured
by immunoblotting with pS485/pT488 anti-XRCC1 polyclonal antibody. Right quantitation of the mRFP-XRCC1161–406 fluorescence at sites of 351 nm
UVA laser damage. Data is expressed as change in mean fluorescence in ten or more cells per construct ± SEM.
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Figure 4. The XRCC1 BRCT1 phosphate-binding pocket is important for
XRCC1 accumulation at sites of H2O2-induced damage and for colocal-
ization with PCNA. (A) U2OS cells were transfected with pEGFP-XRCC1
or pEGFP-XRCC1RK, mock-treated or treated with 10 mM H2O2 for 10
min, and after 15 min recovery in drug-free medium fixed and analysed
by fluorescence microscopy. (B) Left, U2OSGFP-XRCC1 cells were trans-
fected with pCCC-TagRFP to detect endogenous PCNA in the presence
or absence of the PARP inhibitor olaparib (100 nM) and analysed as
above 24 h later. Right, cells were transfected as above and additionally
pulse labelled with EdU (blue) to identify sites of DNA replication. Dot-
ted square denotes the area expanded on the right. (C) U2OS cells were
co-transfected with either pEGFP-XRCC1WT or pEGFP-XRCC1RK and
pCCC-TagRFP plasmid to detect endogenous PCNA. Representative im-
ages are shown.
DISCUSSION
The synthesis of poly (ADP-ribose) (PAR) by PARP1 can
accelerate SSBR, but the molecular mechanism by which
PAR achieves this is unclear (17). One likely role is promot-
ing recruitment of the SSBR scaffold protein, XRCC1 (11–
15), although this idea has proved controversial (18–22). To
further address this possibility we have clarified the mecha-
nism of PAR binding by XRCC1 and addressed its impor-
tance for SSBR and cell survival. PAR binding was initially
ascribed to a degenerate motif present at the C-terminus of
the central BRCT1 domain in XRCC1, comprised of an al-
ternating series of basic/hydrophobic residues and present
in numerous other PAR binding proteins (9). Interestingly,
this motif in XRCC1 harbours a common polymorphism
at amino acid 399 (arginine/glutamine), which in some epi-
demiological studies has been implicated in altered predis-
position to cancer. However, in cellular assays this poly-
morphism does not impact measurably on XRCC1 func-
tion, suggesting that it does not influence PAR binding (36).
Moreover, replacement of five of the basic residues charac-
teristic of this degenerate motif with alanine also fails to
impact on XRCC1 function, suggesting that the degenerate
motif is not, by itself at least, important for PAR binding
(unpublished observations).
Recently, PAR binding by XRCC1 was assigned to a dif-
ferent region of the BRCT1 domain; the highly conserved
phosphate binding pocket in (16). In agreement with Li
et al., we found that the phosphate-binding pocket inter-
acts directly with PAR. However, in contrast to Li et al.,
we did not detect binding to mono(ADP-ribose) (MAR)
by this motif. Indeed, our competition assays indicate that
binding by this motif is highly selective for PAR. We found
that the phosphate-binding pocket confers on XRCC1 the
ability to bind PAR at low concentrations of polymer, as in-
dicated by its greater impact on PAR binding by XRCC1 at
low concentrations of NAD+, in vitro. This might be an ad-
vantage at low levels of SSBs such as those arising endoge-
nously in cells, in which PAR polymer might be present at
a low concentration and distributed at only a small number
of sites across the genome. However, XRCC1 harbouring a
mutated phosphate-binding pocket still bound PAR at high
concentrations of polymer, albeit to a lesser extent thanwild
type XRCC1. This may reflect incomplete ablation of PAR
binding by the R335A/K369A mutation or, alternatively,
weak PAR binding conferred by the degenerate PAR bind-
ing motif described above. Nevertheless, mutation of the
phosphate-binding pocket greatly reduced mRFP-XRCC1
recruitment at sites of UVA laser-induced damage, and also
EGFP-XRCC1 at sites of DNA damage induced by H2O2,
suggesting that this pocket is critical for accumulation of
EGFP-XRCC1 at cellular sites of DNA strand breakage.
Interestingly, the impact ofmutating the phosphate-binding
pocket on XRCC1 accumulation at sites of UVA laser in-
duced damage was greater than incubation with PARP in-
hibitor. This might reflect incomplete inhibition of PAR
synthesis by inhibitor or, alternatively, a low level of pro-
tein ribosylation generated prior to incubation with PARP
inhibitor.
Mutation of the phosphate-binding pocket also greatly
reduced XRCC1 accumulation at sites of PCNA accumula-
tion, suggesting that PAR synthesis also promotes XRCC1
accumulation at sites of damaged replication forks. The
latter is consistent with our model for replication-coupled
SSBR, in which XRCC1 promotes repair of SSBs either
ahead of an approaching fork or after replication fork col-
lapse (35,37). It is also consistent with a role for PARP1 in
regulating fork progression in the presence of DNA strand
breaks (38–41). However, it is important to note that we
have so far only observed XRCC1 accumulation at sites
of ongoing DNA replication in cells co-expressing RFP-
PCNA or anti-PCNA antibody (data not shown). Con-
sequently, we suggest that both approaches perturb nor-
mal PCNA function to some extent, thereby generating
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Figure 5. XRCC1-mediated acceleration of SSBR and cell survival requires the XRCC1 BRCT1 phosphate-binding pocket. (A) XRCC1 protein expression
in XRCC1-mutant EM9 cells stably transfected with empty expression vector (EM9-V) or expression vector encoding either XRCC1-His (EM9-XH)
or XRCC1-HisRK (EM9-XHRK). Cell extracts were fractionated by SDS-PAGE and immunoblotted with anti-XRCC1 Mab (33–2–5) and anti-Actin
antibodies. (B) Clonogenic survival of XRCC1-mutant EM9 cells stably transfected with empty expression vector (EM9-V) or expression vector encoding
either XRCC1-His (EM9-XH) or XRCC1-HisRK (EM9-XHRK). Cells were treated with the indicated concentrations of H2O2 (left) or MMS (right) for
15 min and then in drug free medium for 10–14 days to allow colony formation. Data are the mean (±SEM) of three independent experiments. Where
not visible, error bars are smaller than the symbols. (C) Chromosomal SSBR rates were measured in the above EM9 cell lines in alkaline comet assays
following treatment with 150 MH2O2 for 20 min on ice, followed by recovery in drug-free medium for the indicated time at 37◦C, or with the indicated
concentration ofMMS for 15min at 37◦C tomeasure the accumulation of SSB intermediates during BER.Data are themean (±SEM) of three independent
experiments.
SSBs and/or other sources of replication stress that trigger
PARP1 activation.
Finally, XRCC1 harbouring a mutated phosphate-
binding pocket was unable to restore rapid rates of chro-
mosomal SSBR to XRCC1-mutant EM9 cells, following
treatment with either H2O2 or MMS, and only slightly in-
creased cellular resistance to these genotoxins. This work
thus highlights the importance of the PAR-binding motif
for XRCC1 functionality, both at oxidative breaks induced
by H2O2 and following MMS-induced DNA alkylation.
The latter is particularly intriguing, because MMS-induced
SSBs arise as intermediates of DNA base excision repair
(BER), suggesting that PAR is important for XRCC1 func-
tion during BER. Whereas several reports have suggested
that PARP1 is required during BER following DNA alkyla-
tion (42,43), others have reported that it is dispensable (44–
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46). To reconcile this discrepancy, we previously suggested
that PARP1 may be required to detect SSBs arising during
BER only if the SSB intermediate becomes uncoupled from
the canonical pathway, and/or during replication-coupled
SSBR (35,37). However, in the current work, the PAR-
binding pocket appeared to be required to accelerate most if
not all XRCC1-dependent BER events, as measured by al-
kaline comet assays following MMS treatment. The extent
to which PAR synthesis promotes BER events thus war-
rants further investigation.
In summary, we confirm that PAR binding is mediated
by the phosphate-binding pocket of the XRCC1 BRCT1
domain, and show that the PAR-binding pocket promotes
XRCC1 accumulation at DNA damage globally across the
genome and at sites ofDNA replication stress.We also show
that the phosphate-binding pocket is required for accelera-
tion of SSBR by XRCC1, and for XRCC1-dependent cell
survival, supporting the hypothesis that poly (ADP-ribose)
synthesis is important for XRCC1 recruitment and func-
tion.
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